Virus Dataset Detail

> Detail information for each sample

Dataset Information
Accession GSE226620
Status 2024/6/1
Title CD161 expression of TRM cells counteracts the HPV-associated clinical benefit in oropharyngeal cancer immunotherapy
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing;Other
Summary Oropharyngeal squamous cell carcinoma (OPSCC), a distinct head and neck cancer subtype that develops in the oropharynx, is well known to be categorized into human papillomavirus induced (HPV+) and non-HPV induced (HPV-). While HPV+ OPSCC is reported to be clinically advantageous compared to HPV- OPSCC, the heterogeneous responses in HPV+ OPSCC during immunotherapy treatment have not been well characterized at the molecular level. In this study, we assess both tumor and immune cells of the OPSCC tumor microenvironment (TME) via single-cell RNA sequencing (scRNA-seq) and single-cell TCR sequencing (scTCR-seq). By dissecting the transcriptome of OPSCC tumor cells, we find that cancer cell transcriptional diversity may be a strong factor in negating HPV associated clinical benefits. By assessing immune cells, we observed molecular antiviral and anti-tumor characteristics of T cells that is associated with HPV infection, and key cell-cell interaction differences among resident memory T cells (Trm), follicular helper T cells, and B cells. Importantly, we identify a novel molecular state within the HPV+ OPSCC that is distinguished by the expression KLRB1 (CD161) in the Trm that inhibits anti-tumor activity, which may further explain the heterogeneous clinical benefits of HPV+OPSCC. Association of KLRB1 expression of Trm and immunotherapy outcome was confirmed via immunofluorescence analysis, suggesting CD161 as a novel therapeutic target to improve cancer treatment of HPV+ OPSCC.
Samples
GSM ID Sample info Characteristics Description
GSM7080438 P29, positive tissue:Oropharynx, HNSCC; Sex:M; age:47; tumor stage:II; hpv state:+ 10x Genomics
GSM7080439 P20, positive tissue:Oropharynx, HNSCC; Sex:M; age:45; tumor stage:II; hpv state:+ 10x Genomics
GSM7080440 P23, positive tissue:Oropharynx, HNSCC; Sex:M; age:64; tumor stage:II; hpv state:+ 10x Genomics
GSM7080441 P25, positive tissue:Oropharynx, HNSCC; Sex:M; age:62; tumor stage:III; hpv state:+ 10x Genomics
GSM7080442 P27, negative tissue:Oropharynx, HNSCC; Sex:M; age:50; tumor stage:III; hpv state:- 10x Genomics
GSM7080443 P28, negative tissue:Oropharynx, HNSCC; Sex:M; age:68; tumor stage:III; hpv state:- 10x Genomics
GSM7080444 P31, positive tissue:Oropharynx, HNSCC; Sex:M; age:60; tumor stage:III; hpv state:+ 10x Genomics
GSM7080445 P30, negative tissue:Oropharynx, HNSCC; Sex:F; age:68; tumor stage:IVB; hpv state:- 10x Genomics
GSM7080446 P32, negative tissue:Oropharynx, HNSCC; Sex:M; age:69; tumor stage:IVA; hpv state:- 10x Genomics
GSM7157425 P18, positive, TCR tissue:Oropharynx, HNSCC; Sex:M; age:41; tumor stage:II; hpv state:+ 10x Genomics
GSM7157426 P29, positive, TCR tissue:Oropharynx, HNSCC; Sex:M; age:47; tumor stage:II; hpv state:+ 10x Genomics
GSM7157427 P20, positive, TCR tissue:Oropharynx, HNSCC; Sex:M; age:45; tumor stage:II; hpv state:+ 10x Genomics
GSM7157428 P23, positive, TCR tissue:Oropharynx, HNSCC; Sex:M; age:64; tumor stage:II; hpv state:+ 10x Genomics
GSM7157429 P25, positive, TCR tissue:Oropharynx, HNSCC; Sex:M; age:62; tumor stage:III; hpv state:+ 10x Genomics
GSM7157430 P27, negative, TCR tissue:Oropharynx, HNSCC; Sex:M; age:50; tumor stage:III; hpv state:- 10x Genomics
GSM7157431 P28, negative, TCR tissue:Oropharynx, HNSCC; Sex:M; age:68; tumor stage:III; hpv state:- 10x Genomics
GSM7157432 P31, positive, TCR tissue:Oropharynx, HNSCC; Sex:M; age:60; tumor stage:III; hpv state:+ 10x Genomics
GSM7157433 P30, negative, TCR tissue:Oropharynx, HNSCC; Sex:F; age:68; tumor stage:IVB; hpv state:- 10x Genomics
GSM7157434 P32, negative, TCR tissue:Oropharynx, HNSCC; Sex:M; age:69; tumor stage:IVA; hpv state:- 10x Genomics
GSM7080427 HPV01, positive tissue:Oropharynx, HNSCC; Sex:M; age:69; tumor stage:II; hpv state:+ 10x Genomics
GSM7080428 HPV02, positive tissue:Oropharynx, HNSCC; Sex:F; age:71; tumor stage:IV; hpv state:+ 10x Genomics
GSM7080429 HPV03, positive tissue:Oropharynx, HNSCC; Sex:M; age:46; tumor stage:I; hpv state:+ 10x Genomics
GSM7080430 HPV04, positive tissue:Oropharynx, HNSCC; Sex:M; age:63; tumor stage:II; hpv state:+ 10x Genomics
GSM7080431 HPV05, positive tissue:Oropharynx, HNSCC; Sex:M; age:65; tumor stage:0; hpv state:+ 10x Genomics
GSM7080432 HPV06, positive tissue:Oropharynx, HNSCC; Sex:M; age:61; tumor stage:0; hpv state:+ 10x Genomics
GSM7080433 HPV07, positive tissue:Oropharynx, HNSCC; Sex:M; age:49; tumor stage:IVB; hpv state:+ 10x Genomics
GSM7080434 HPV08, positive tissue:Oropharynx, HNSCC; Sex:M; age:69; tumor stage:0; hpv state:+ 10x Genomics
GSM7080435 HPV09, negative tissue:Oropharynx, HNSCC; Sex:M; age:65; tumor stage:0; hpv state:- 10x Genomics
GSM7080436 HPV10, negative tissue:Oropharynx, HNSCC; Sex:M; age:72; tumor stage:III; hpv state:- 10x Genomics
GSM7080437 P18, positive tissue:Oropharynx, HNSCC; Sex:M; age:41; tumor stage:II; hpv state:+ 10x Genomics
Platform GPL20795  : HiSeq X Ten (Homo sapiens)
Literature 38857913  
Download Download scRNA Analysis Data  
scRNA-seq UMAP